The influenza A virus is encoded by eight individual single-stranded segments of RNA. Each segment must serve as the material for both making protein and new segments, processes called transcription and replication. As each strand must perform both functions, it is imperative that the virus prioritize these processes, starting with transcription and then switching to replication.
Mount Sinai researchers have, for the first time, identified a small-viral RNA (svRNA), derived from the virus, that is integral to the switch from transcription to replication. Inhibiting svRNA from making this switch would stymie replication and thus slow or halt the spread of the virus. Because segment ends and replication strategies used for influenza B and C are similar to those of influenza A, this discovery can lead to a universal treatment for people suffering from the disease. It would also be effective against the H1N1 swine flu virus.
"The implications of this study are very exciting," said Benjamin tenOever, PhD, Assistant Professor of Microbiology at Mount Sinai School of Medicine and corresponding author of the study. "While each segment encodes different viral products, the svRNAs remain consistent, both between segments and across viral strains. If we can block the availability of svRNA we can inhibit the switch to replication, thereby stopping viral spread. As an added bonus, if the virus remains stuck in transcription, it will continue to produce proteins, ultimately strengthening the antibody response."
The small RNA component was originally identified through a process called deep sequencing. This revolutionary new technique allows scientists to obtain millions of small RNAs from cells in a completely unbiased fashion. The technique was applied to lung cells infected with influenza A virus and ultimately led to the discovery of the first small RNA component ever identified from this family of viruses.
"Questions remain about exactly how the svRNAs function," said Dr. tenOever. "We're also hoping to engineer a means of delivering RNA-based antagonists into the body's system as a means of inhibiting svRNA function. We're still a few years off from solving the entire puzzle. However, by finding this one piece, a universal treatment for all strains of influenza is within reach of becoming a reality."
About The Mount Sinai Medical Center
The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and Mount Sinai School of Medicine. Established in 1968, Mount Sinai School of Medicine is one of few medical schools embedded in a hospital in the United States. It has more than 3,400 faculty in 32 departments and 15 institutes, and ranks among the top 20 medical schools both in National Institute of Health funding and by U.S. News & World Report. The school received the 2009 Spencer Foreman Award for Outstanding Community Service from the Association of American Medical Colleges.
The Mount Sinai Hospital, founded in 1852, is a 1,171-bed tertiary- and quaternary-care teaching facility and one of the nation's oldest, largest and most-respected voluntary hospitals. In 2009, U.S. News & World Report ranked The Mount Sinai Hospital among the nation's top 20 hospitals based on reputation, patient safety, and other patient-care factors. Nearly 60,000 people were treated at Mount Sinai as inpatients last year, and approximately 530,000 outpatient visits took place.
Mount Sinai Press Office | EurekAlert!
NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases
Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences
Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...
On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...
The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...
At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.
When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...
At the ILA Berlin, hall 4, booth 202, Fraunhofer FHR will present two radar sensors for navigation support of drones. The sensors are valuable components in the implementation of autonomous flying drones: they function as obstacle detectors to prevent collisions. Radar sensors also operate reliably in restricted visibility, e.g. in foggy or dusty conditions. Due to their ability to measure distances with high precision, the radar sensors can also be used as altimeters when other sources of information such as barometers or GPS are not available or cannot operate optimally.
Drones play an increasingly important role in the area of logistics and services. Well-known logistic companies place great hope in these compact, aerial...
16.03.2018 | Event News
13.03.2018 | Event News
08.03.2018 | Event News
16.03.2018 | Earth Sciences
16.03.2018 | Physics and Astronomy
16.03.2018 | Life Sciences